TY - JOUR
AU1 - Giamarellos-Bourboulis, E.
AU2 - Grecka, P.
AU3 - Giamarellou, Helen
AB - Drugs 49 (Suppl. 2): 203-204, 1995 0012-6667/95/0002-0203/$01.00/0 © Adis International limited. All rights reserved. Comparative In Vitro Activity of Ciprofloxacin vs 8 Antimicrobial Agents against Nosocomial Multiresistant P. aeruginosa Strains E.J. Giamarellos-Bourboulis, P Grecka and H. Giamarellou 1st Department of Propedeutic Medicine, Athens University School of Medicine, Athens, Greece Pseudomonas aeruginosa is a major nosoco­ meropenem and imipenem 4 mg/L, ceftazidime mial pathogen associated with high mortality and 8 mg/L, ticarcillin and piperacillin 64 mg/L, morbidity. In Southern Europe, resistance of P. gentamicin and tobramycin 4 mg/L and amikacin aeruginosa isolates to ciprofloxacin has increased 16 mg/L. Minimum bactericidal concentrations dramatically over the last decade,lll and is now ap­ (MBCs) were determined as 99.9% of killing after proaching 30%. On this basis, we investigated the plating the content of the clear wells on to in vitro activity of ciprofloxacin against multiresis­ McConkey agar. tant strains 5 years after its introduction into the Ciprofloxacin was found to be the fourth most Greek market. potent in vitro antipseudomonal agent, inhibiting 147 different P. aeruginosa strains derived from 19.7% of strains at the breakpoint; meropenem, patients with a variety of nosocomial infections ceftazidime, imipenem, piperacillin, amikacin, were used. The strains were isolated 
TI - Comparative In Vitro Activity of Ciprofloxacin vs 8 Antimicrobial Agents against Nosocomial Multiresistant P. aeruginosa Strains
JF - Drugs
DO - 10.2165/00003495-199500492-00042
DA - 2012-11-28
UR - https://www.deepdyve.com/lp/springer-journals/comparative-in-vitro-activity-of-ciprofloxacin-vs-8-antimicrobial-JuDgRfr6ok
SP - 203
EP - 204
VL - 49
IS - 2
DP - DeepDyve
ER -